Seaport Therapeutics, Inc. Common Stock
Follow $SPTX
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $SPTX by emailVeridion Score
BETALOW CONF · 4 of 6 factors measuredHighest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is SPTX moving today?
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
SPTX overview
Related filings and maps
Congress activity in SPTX
No receipt-qualified Congressional disclosure is present for SPTX in the cached public ledger.
SPTX contract awards, year to date.
Public federal awards linked to this ticker.
SPTX lobbying filings, year to date.
Registered lobbying filings matched to Seaport Therapeutics, Inc. Common Stock.